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Low hematocrit predicts contrast-induced nephropathy after
percutaneous coronary interventions.
Background. The relationship between low hematocrit and
contrast-induced nephropathy has not been investigated.
Methods. Of 6,773 consecutive patients treated with percu-
taneous coronary intervention, contrast-induced nephropathy
(an increase of ≥25% or ≥0.5 mg/dL in preprocedure serum
creatinine, at 48 hours postprocedure) occurred in 942 (13.9%)
patients.
Results. Rates of contrast-induced nephropathy steadily in-
creased as baseline hematocrit quintile decreased (from 10.3%
in the highest quintile to 23.3% in the lowest quintile) (v 2 for
trend, P < 0.0001). Stratification by baseline estimated glomeru-
lar filtration rate (eGFR) and baseline hematocrit showed that
the rates of contrast-induced nephropathy were the highest
(28.8%) in patients who had the lowest level for both baseline
eGFR and hematocrit. Patients with the lowest eGFR but rel-
atively high baseline hematocrit values had remarkably lower
rates of contrast-induced nephropathy (15.8%, 12.3%, 17.1%,
and 15.4% in 2nd, 3rd, 4th, and 5th quintiles of baseline hemat-
ocrit, respectively) (P < 0.0001). The rates of contrast-induced
nephropathy increased with increment in change in hemat-
ocrit. Patients in the lowest quintile of baseline hematocrit
with absolute hematocrit drop >5.9% had almost doubled rates
of contrast-induced nephropathy compared with patients with
hematocrit change <3.4% (38.1% vs. 18.8%, respectively) (P <
0.0001). By multivariate analysis, lower baseline hematocrit
was an independent predictor of contrast-induced nephropathy;
each 3% decrease in baseline hematocrit resulted in a signifi-
cant increase in the odds of contrast-induced nephropathy in pa-
tients with and without chronic kidney disease (11% and 23%,
respectively). When introduced into the multivariate model in-
stead of baseline hematocrit, change in hematocrit also showed
a significant association with contrast-induced nephropathy.
Conclusion. Lower hematocrit is an important risk factor for
contrast-induced nephropathy. Whether correcting the hema-
tocrit prepercutaneous coronary intervention might decrease
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the rates of contrast-induced nephropathy should be addressed
in a prospectively designed trial.
Contrast-induced nephropathy is one of the most fre-
quent causes of in-hospital renal function impairment. It
is associated with increased 1-year mortality in patients
undergoing percutaneous coronary interventions [1–3].
Although the exact pathogenesis of contrast-induced
nephropathy is not known, several mechanisms have
been implicated, including ischemic injury, direct cyto-
toxicity on renal structures, oxidative stress, apoptosis,
and decline in renal blood flow [4–8].
Chronic kidney disease, diabetes mellitus, older age,
and increased volume of contrast media are the well-
known risk factors for the development of contrast-
induced nephropathy [9–12]. Anemia might be one of
the factors deteriorating renal ischemia [13]. However,
the significance of anemia in the development of contrast-
induced nephropathy has not been studied. We therefore
examined our interventional cardiology database to de-
termine the effect of periprocedural hematocrit on rates
of contrast-induced nephropathy in patients treated with
percutaneous coronary interventions.
METHODS
Study population
This study is based on 6773 consecutive patients un-
dergoing percutaneous coronary interventions during a
6-year period at a single tertiary care center. Patients
treated with percutaneous coronary interventions for
acute myocardial infarction, patients known to have neo-
plastic disorders, and those on dialysis were excluded
from the analysis. For patients who underwent more
than one revascularization procedure during the study
period, only the first intervention was included. All pa-
tients provided written informed consent. Data were en-
tered in a database that contained demographic, clinical,
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angiographic, and 1-year follow-up information. These
data collection and analyses methods have been de-
scribed in detail previously [14].
Percutaneous coronary intervention was performed
using standard techniques. All patients received rou-
tine intravenous hydration with half normal saline at
1 mL/kg/hour for 4 to 12 hours before the procedure and
for 18 to 24 hours after the procedure.
The specific type of revascularization procedure was
at the discretion of the interventional cardiologist. All
patients were treated with aspirin 325 mg daily at least
24 hours preprocedure and continued indefinitely after-
ward. Patients who underwent stenting also received ei-
ther ticlopidine 250 mg twice daily or clopidogrel 75 mg
daily for 4 weeks. Heparin was administered during the
procedure in a dose sufficient to maintain an activated
clotting time of 250 to 300 seconds. All other treatments
were at the discretion of the physicians, whether before,
during, or after the procedure.
Definitions
Baseline hematocrit was the last value before the per-
cutaneous coronary intervention; nadir hematocrit was
the lowest postprocedure value; and change in hematocrit
was calculated as the difference between baseline and
nadir values. Chronic kidney disease was a baseline esti-
mated glomerular filtration rate (eGFR) of <60 mL/min/
1.73 m2 [Levey modified Modification of Diet in Renal
Disease (MDRD) formula] [15, 16]. Contrast-induced
nephropathy was an increase of ≥25% or ≥0.5 mg/dL
in prepercutaneous coronary intervention serum creati-
nine at 48 hours postpercutaneous coronary intervention
[1, 17]. Hypotension was systolic blood pressure <80 mm
Hg for at least 1 hour requiring inotropic support with
medications or intra-aortic balloon pump within 24 hours
periprocedurally.
Statistical analysis
Patients were divided into quintiles of hematocrit (the
1st and 5th quintiles corresponded to the lowest and
highest values of hematocrit, respectively). Continuous
variables are expressed as mean ± standard deviation
(SD), and categorical data were presented as frequencies.
Differences among groups were compared using analy-
sis of variance (ANOVA) for continuous variables and
chi-square statistics for categorical variables. All tests of
significance were two-sided.
Multivariate predictors of contrast-induced nephropa-
thy were determined using logistic regression with step-
wise selection with entry and exit criteria of P < 0.1. A
two-sided 95% confidence interval (CI) was constructed
around the point estimate of the odds ratio (OR). The
variables chosen by the model included age, gender, body
surface area, advanced congestive heart failure (New
York Heart Association class III or IV), diabetes mellitus,
present or past smoking, history of myocardial infarction,
coronary artery bypass grafting, systemic hypertension,
peripheral arterial disease, volume and type of contrast
media, periprocedural hypotension, elective use of intra-
aortic balloon pump (i.e., in the setting other than hy-
potension and/or congestive heart failure), preprocedure
medications, baseline eGFR, and baseline hematocrit.
RESULTS
Baseline clinical and procedural characteristics of the
patients by quintiles of baseline hematocrit are presented
in Table 1. Patients in lower quintiles of hematocrit were
older, more frequently female and African American,
had a higher prevalence of hypertension, diabetes, pe-
ripheral arterial disease, and congestive heart failure, and
lower rates of current or past smoking. In addition, his-
tory of myocardial infarction, coronary bypass surgery,
and stroke were significantly more common in patients
in the lower quintiles. Lower hematocrit values were also
associated with smaller body surface areas, lower left
ventricle ejection fractions, and lower eGFR. Patients
in lower quintiles more often underwent percutaneous
coronary intervention for unstable angina. Consistent
with worse baseline renal function, patients with lower
baseline hematocrit received less contrast media, and
were more likely to receive low osmolar contrast agents.
Finally, patients in the lower quintiles were less likely to
be treated with aspirin and more likely to be treated with
angiotensin-converting enzyme (ACE) inhibitors.
A significant number of patients in the lowest quin-
tile of baseline hematocrit were more likely to experi-
ence periprocedural hypotension and hemodynamic sup-
port with intra-aortic ballon pump (Table 1). Regarding
procedure-related bleeding complications, the incidence
of groin hematoma (blood accumulation ≥2 × 4 cm or
those requiring transfusion or resulting in prolonged hos-
pitalization) was the highest in the 1st quintile of baseline
hematocrit (12.4%) compared with the 2nd to 5th quin-
tiles (7.9%, 7.9%, 7.0%, and 9.3%, respectively) (P <
0.0001).
Baseline hematocrit, eGFR, and rates of
contrast-induced nephropathy
In the entire cohort, contrast-induced nephropathy de-
veloped in a total of 942 (13.9%) patients. A significant
trend toward increase in contrast-induced nephropathy
rates was observed with decrements of baseline hemat-
ocrit value from 10.3% in the highest quintile to 10.6%,
11.8%, 13.3%, and 23.3% in the lower quintiles, respec-
tively (v 2 for trend P < 0.0001).
Given a strong association between hematocrit and
renal function [18], further analysis was performed in
subgroups of patients stratified by quartiles of baseline
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Table 1. Baseline patient and procedural characteristics
Quintile 1 Quintile 2 Quintile 3 Quintile 4 Quintile 5
(hematocrit (hematocrit (hematocrit (hematocrit (hematocrit
<36.8%) ≥36.8% to <39.9%) ≥39.9% to <42.3%) ≥42.3% to <44.8%) ≥44.8%)
(N = 1380) (N = 1308) (N = 1376) (N = 1356) (N = 1353) P valuea
Hematocrit, mean ± SD % 33.6 ± 2.8 38.5 ± 0.9 41.1 ± 0.7 43.5 ± 0.7 47.1 ± 2.1 <0.0001
Age, mean ± SD years 68.5 ± 11.2 65.6 ± 10.7 64.0 ± 10.9 62.5 ± 11.0 61.0 ± 10.7 <0.0001
Male% 43.3 58.2 72.5 84.2 92.4 <0.0001
African American % 9.1 7.5 6.0 5.2 4.1 <0.0001
Hypercholesterolemia % 61.7 69.4 68.5 69.4 69.4 <0.0001
Hypertension % 68.5 65.1 60.3 57.8 56.5 <0.0001
Diabetes mellitus % 36.8 30.9 28.3 26.8 23.3 <0.0001
Insulin-treated diabetes mellitus % 18.8 12.7 10.9 10.2 8.3 <0.0001
Family history of coronary artery
disease %
50.3 60.8 60.2 62.9 64.2 <0.0001
Current smoking % 14.2 16.0 15.6 18.6 20.1 0.0002
History of smoking % 36.7 38.6 42.2 42.7 42.1 <0.0001
Peripheral arterial disease % 23.6 18.5 15.3 14.9 13.7 <0.0001
Unstable angina % 44.1 38.7 34.5 31.4 28.5 <0.0001
Left ventricular ejection fraction,
mean ± SD
0.45 ± 0.14 0.47 ± 0.14 0.47 ± 0.13 0.48 ± 0.13 0.48 ± 0.13 0.0002
Previous myocardial infarction % 55.5 51.9 52.5 51.7 50.6 0.01
Previous coronary bypass grafting % 41.0 37.0 36.9 35.5 31.9 <0.0001
Previous stroke % 14.8 12.1 10.6 9.4 7.9 <0.0001
Congestive heart failure % 7.5 4.8 3.6 3.1 3.3 <0.0001
Baseline creatinine, mean ± SD mg/dL 1.24 ± 0.67 1.11 ± 0.52 1.08 ± 0.48 1.07 ± 0.25 1.11 ± 0.54 <0.0001
Baseline estimated glomerular filtration
rate, mean ± SD mL/min/1.73 m2
63.54 ± 23.58 71.69 ± 21.76 74.84 ± 20.49 76.40 ± 18.32 76.57 ± 18.34 <0.0001
Patients with estimated glomerular
filtration rate <60 mL/min/1.73 m2 %
45.9 30.7 22.7 18.0 15.5 <0.0001
Body surface area, mean ± SD m2 1.84 ± 0.22 1.91 ± 0.22 1.96 ± 0.22 2.00 ± 0.20 2.03 ± 0.20 <0.0001
Preprocedure medications %
Aspirin 96.0 97.3 97.6 98.1 98.1 0.003
Thienopyridine 53.5 58.8 57.8 58.4 61.4 0.001
Angiotensin-converting enzyme
inhibitor
31.2 27.7 26.1 23.4 21.7 <0.0001
Low-molecular-weight heparin 7.7 9.1 7.9 9.3 9.0 0.46
Procedural data
Hypotension % 13.4 10.0 8.9 7.9 6.9 <0.0001
Intra-aortic balloon pump use % 11.3 8.6 7.4 6.2 4.6 <0.0001
Contrast media volume,
mean ± SD mL
254 ± 122 255 ± 120 266 ± 125 271 ± 130 272 ± 123 0.0002
Low osmolar contrast agent % 59.7 49.2 48.6 42.4 41.7 <0.0001
aChi-square statistics for categorical variables and analysis of variance for continuous variables.
eGFR and quintiles of baseline hematocrit. As shown in
Figure 1, the rates of contrast-induced nephropathy in the
identified 20 subgroups varied from 6.7% to 28.8%, being
the highest in patients who had the lowest level for both
baseline eGFR and baseline hematocrit. A significant
trend toward increase in contrast-induced nephropathy
rates was observed with decrements of baseline hemat-
ocrit value across all (P < 0.0001) but 3rd quartile (P =
0.32) of baseline eGFR value.
Change in hematocrit and rates of
contrast-induced nephropathy
Procedure-related change in hematocrit occurred in
6762 patients (99.8%). As expected, most of the pa-
tients (94.2%) had a decrease in hematocrit postproce-
dure compared with baseline value. To study the impact of
change in hematocrit across each of the quintiles of base-
line hematocrit, the patients were further stratified into
tertiles of change in hematocrit (1st tertile corresponded
to a drop in hematocrit <3.4% or increase in hematocrit;
2nd tertile, a drop in hematocrit from ≥3.4% to <5.9%;
and 3rd tertile, a drop in hematocrit ≥5.9%). As shown
in Figure 2, the rates of contrast-induced nephropathy
increased with increment in change in hematocrit across
all quintiles of baseline hematocrit. Contrast-induced
nephropathy developed 1.3 to 2.8 times more frequently
in patients with the highest drop in hematocrit com-
pared to the patients with the lowest change in hema-
tocrit. Of importance, the effect of hematocrit change
was especially pronounced in patients in the 2 lowest
quintiles of baseline hematocrit (1st and 2nd). Patients
with hematocrit change >5.9% had almost doubled rates
of contrast-induced nephropathy compared with the pa-
tients with hematocrit change <3.4% (38.1% vs. 18.8%,
respectively); and patients with hematocrit change from
3.4% to 5.9% had almost tripled rates of contrast-induced
nephropathy (24.3% vs. 8.5%, respectively).
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Fig. 1. Risk of contrast-induced nephropathy in relation to baseline hematocrit and estimated glomerular filtration rate (eGFR).
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Fig. 2. Risk of contrast-induced nephropathy in relation to baseline hematocrit and procedure-related change in hematocrit.
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Table 2. Multivariate predictors of contrast-induced nephropathy
Odds ratio 95% CI P value
Model A (patients with baseline chronic kidney disease)
Baseline hematocrit (3%
decrease)
1.11 1.02–1.22 0.02
Estimated glomerular filtration
rate (10 mL/min/1.73 m2
decrease)
1.58 1.38–1.81 <0.0001
Volume of contrast media
(increment by 100 mL)
1.30 1.15–1.47 <0.0001
Hypotension 2.12 1.40–3.23 0.0004
Diabetes mellitus 1.53 1.11–2.12 0.009
Hypertension 1.80 1.20–2.72 0.005
Ejection fraction <40% 1.43 0.99–2.05 0.06
Intra-aortic balloon pump use 1.73 1.01–2.97 0.05
Model B (patients without baseline chronic kidney disease)
Baseline hematocrit (3%
decrease)
1.23 1.14–1.31 <0.0001
Estimated glomerular filtration
rate (10 mL/min/1.73 m2
decrease)
0.79 0.74–0.85 <0.0001
Volume of contrast media
(increment by 100 mL)
1.31 1.21–1.42 <0.0001
Hypotension 2.39 1.70–3.37 <0.0001
Diabetes mellitus 1.57 1.23–1.99 0.0002
Hypertension 1.41 1.12–1.79 0.004
Ejection fraction <40% 1.68 1.27–2.21 0.0002
Peripheral arterial disease 1.45 1.09–1.95 0.01
Multivariate analysis
By multivariate analysis, lower baseline hematocrit
was identified as an independent predictor of contrast-
induced nephropathy in both patients with and without
baseline chronic kidney disease (Table 2). Each 3% de-
crease in baseline hematocrit resulted in an 11% increase
in the odds of contrast-induced nephropathy (95% CI
1.02–1.22) (P = 0.02) in patients with chronic kidney dis-
ease, and a 23% increase in the odds of contrast-induced
nephropathy (95% CI 1.14–1.31) (P < 0.0001) in pa-
tients without chronic kidney disease. There was statisti-
cally significant interaction (P =0.0001) between baseline
hematocrit and baseline eGFR when specifically exam-
ined for the interaction term in the multivariable model.
No significant interaction was observed between baseline
hematocrit and other variables in the multivariate model.
As shown in Figure 3, after adjustment for the potential
confounders in the entire cohort, patients in the lowest
quintile of baseline hematocrit had more than doubled
odds of contrast-induced nephropathy compared with
the patients in the highest (or 5th) quintile [odds ratio
(95% CI) = 2.28 (1.71, 3.04)] (P < 0.0001). In contrast,
patients in the 2nd, 3rd, and 4th quintiles of baseline
hematocrit did not have significantly different odds of
contrast-induced nephropathy compared to the patients
in the highest quintile. An increased risk of contrast-
induced nephropathy was observed in the lowest quin-
tiles of baseline hematocrit for both males (hematocrit
value <38.4%) and females (hematocrit value <34.4%)
1.0
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Fig. 3. Covariate adjusted odds ratios and 95% confidence interval
of contrast-induced nephropathy in the entire cohort subdivided by
baseline hematocrit quintiles. The calculations were performed using
the highest (5th) quintile as a reference group.
compared with the highest quintiles (hematocrit value
>45.6% and >41.7%, respectively) [odds ratio (95% CI)
= 2.23 (1.56, 3.17)] (P < 0.0001) for males and 1.60 (1.02,
2.51) (P = 0.04 for females). Males in the 2nd quintile
of baseline hematocrit (hematocrit value from 38.4% to
41.2%) also had significantly increased odds of contrast-
induced nephropathy compared with the highest quintile
[odds ratio (95% CI) = 1.51 (1.04, 2.18)] (P = 0.03).
When change in hematocrit (instead of baseline hema-
tocrit) was introduced into the multivariate model, it also
showed a significant association with contrast-induced
nephropathy. Each 3% drop in hematocrit (known to
correspond approximately to 1 g/dL of hemoglobin) re-
sulted in a 30% increase in the odds of contrast-induced
nephropathy (95% CI 1.16–1.44) (P < 0.0001) in patients
with baseline chronic kidney disease and a 26% increase
in the odds of contrast-induced nephropathy in patients
without chronic kidney disease (95% CI 1.16–1.36) (P <
0.0001).
DISCUSSION
The principal findings of this study, the first such inves-
tigation of the impact of low hematocrit on the develop-
ment of contrast-induced nephropathy in patients treated
with percutaneous coronary interventions, are (1) there
was a significant and independent relationship between
low hematocrit and increased risk of contrast-induced
nephropathy in patients undergoing iodinated contrast
exposure; (2) this relationship was not linear nor graded
with a potential threshold of hematocrit that increased
the risk for contrast-induced nephropathy; (3) despite
significant interaction between the baseline hematocrit
and eGFR, the effect of lower eGFR was modified by
Nikolsky et al: Hematocrit and contrast nephropathy post-PCI 711
higher hematocrit; and (4) a procedure-related drop in
hematocrit was an independent prognostic determinant
of contrast-induced nephropathy regardless of baseline
hematocrit, although being especially detrimental in pa-
tients with a lower hematocrit level.
In this study, only patients in the lowest quintile
of baseline hematocrit (hematocrit value <36.8%) ap-
peared to have a significantly increased risk of contrast-
induced nephropathy compared with the patients in the
highest quintile (≥44.8%). The threshold of baseline
hematocrit that was associated with increased rates of
contrast-induced nephropathy was <41.2% for males and
<34.4% for females. Following the proximity of the estab-
lished hematocrit thresholds to those used by the World
Health Organization for the definition of anemia (hema-
tocrit value <39% for men and <36% for women) [19],
we examined an association between contrast-induced
nephropathy and anemia as a binary variable. When ane-
mia was introduced into the multivariate model instead
of baseline hematocrit, it was also an independent pre-
dictor of contrast-induced nephropathy in both patients
with chronic kidney disease [odds ratio (95% CI) = 1.57
(1.13–2.18)] (P = 0.0006) and in patients without chronic
kidney disease [odds ratio (95% CI) = 1.56 (1.21–2.02)]
(P = 0.0007).
In the present study, baseline hematocrit level was asso-
ciated with higher rates of contrast-induced nephropathy
in patients with different baseline eGFR levels. By strat-
ifying the patients into subgroups based on their eGFR
and hematocrit values, we identified a subgroup of pa-
tients who had low levels for both hematocrit and eGFR
and who had a significantly increased risk of contrast-
induced nephropathy (28.8%). Most notably, however,
patients with the same values of eGFR but higher base-
line hematocrit values had remarkably lower rates of
contrast-induced nephropathy (15.8%, 12.3%, 17.1%,
and 15.4% in the 2nd, 3rd, 4th, and 5th quintiles of base-
line hematocrit, respectively) compared with the patients
with the lowest level of baseline hematocrit. At the same
time, the patients with the highest eGFR but lowest hema-
tocrit had incidence of contrast-induced nephropathy of
27.1%, similar to that of the patients having low level
for both eGFR and hematocrit. These data allow the
assumption that higher hematocrit might attenuate the
risk of contrast-induced nephropathy in patients with low
eGFR.
The results of multivariate analysis obtained in this
study deserve special attention. Identified by logistic
regression, predictors of contrast-induced nephropa-
thy were mostly similar in patients with and without
baseline chronic kidney disease. However, decrease in
eGFR significantly increased the risk of contrast-induced
nephropathy in patients with chronic kidney disease (as
expected) while paradoxic decrease in rates of contrast-
induced nephropathy was observed in patients without
chronic kidney disease. While the significance of the lat-
ter finding is not clear, one possible explanation is that
the abbreviated MDRD formula used in this study for
the calculation of eGFR has been developed in a popu-
lation with chronic kidney disease while it has not been
validated in large-scale studies in subjects without renal
disease and/or in patients with different conditions (e.g.,
diabetes mellitus) [15]. Of note, approximately one forth
of patients with eGFR >60 mL/min/1.73 m2 in this study
(26.3%) had diabetes.
What are the possible mechanisms to explain an as-
sociation between lower hematocrit and higher rates
of contrast-induced nephropathy? In our study, pa-
tients with lower hematocrit were older, had more dia-
betes, congestive heart failure, and worse baseline renal
function (factors all known to increase rates of contrast-
induced nephropathy after percutaneous coronary in-
tervention); however, this does not entirely explain the
obtained results [9–12].
Patients in the lowest quintile of baseline hematocrit
had higher rates of periprocedural hypotension. Con-
sequently, these patients were more likely to receive
intensive fluid replacement therapy resulting in lower
hematocrit due to hemodilution. However, the rather low
incidence of hypotension preprocedure (1.1% of the en-
tire cohort, with no significant differences between quin-
tiles), coupled with the lack of significant interaction
between baseline hematocrit and hypotension assessed
specifically in the multivariate model, allows the assump-
tion that an association between low baseline hematocrit
with higher contrast-induced nephropathy rates is prob-
ably not related solely to hypotension.
Patients with severe congestive heart failure (New
York Heart Association class IV) are also known to have
low hematocrit because of hemodilution [20]. However,
the proportion of these patients was quite low in this study
(1.5% of the entire cohort).
The difference in the type of contrast media might in-
fluence the obtained results. Recent studies suggest that
nonionic low osmolar agents are less nephrotoxic, es-
pecially in patients with renal impairment [21, 22]. In
this study, all patients received a nonionic contrast agent,
and patients with lower hematocrit were more frequently
treated with less nephrotoxic low osmolar contrast agents.
In addition, by multivariate analysis, the type of contrast
agent was not a predictor of contrast-induced nephropa-
thy, thus making the utilization of different types of con-
trast media during percutaneous coronary intervention
an unlikely factor influencing the results.
Anemia-induced deterioration of renal ischemia may
be one plausible explanation of the higher incidence of
contrast-induced nephropathy in patients with low hema-
tocrit. Experimental studies have demonstrated the detri-
mental role of anemia in rats with gentamicin-induced
nephropathy in the form of selective damage to renal
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proximal convoluted tubules along with reduced erythro-
poietin response to ischemia [13, 23]. Erythropoietin is
known to inhibit apoptotic cell death, enhance tubular
epithelial regeneration, and promote renal functional re-
covery in hypoxic and ischemic renal injury, the pathways
believed to be implicated in the pathogenesis of contrast-
induced nephropathy [24].
Our study also highlights the negative impact of
procedure-related blood loss in the development of
contrast-induced nephropathy. The detrimental influence
related to bleeding volume depletion on kidney func-
tion is well known. However, an even relatively small
blood loss may be hazardous. In this study, periprocedu-
ral decrease in hematocrit significantly increased the rates
of contrast-induced nephropathy regardless of baseline
hematocrit value. Yet, patients with initially low hemat-
ocrit levels were especially prone to the development of
contrast-induced nephropathy.
Limitations
This is a retrospective study, although the data were
collected prospectively by independent monitors and en-
tered into a dedicated database. Because the operators
were not blinded to the clinical and laboratory infor-
mation including baseline hematocrit level and renal
function parameters, additional measures to prevent
contrast-induced nephropathy might be undertaken in
selective patients. Data on periprocedural hydration vol-
ume, urine output, and nephrotoxic medications were
not available in our database. Of the three most com-
monly measured red blood cell parameters used—red
blood cell count, hemoglobin, and hematocrit—only the
latter was available. We also did not have data on ery-
thropoietin levels, plasma volume, or red blood cell
mass, information that might provide better understand-
ing of the role of low hematocrit in the development
of contrast-induced nephropathy. Even after multivari-
ate adjustment, low hematocrit remained an independent
predictor of contrast-induced nephropathy; multivariate
models cannot entirely account for the baseline differ-
ences, and adjusted effects still may be influenced by
residual confounding. Additional clinical measurements
not included in this analysis (e.g., postprocedure blood
transfusions) may also interact with contrast-induced
nephropathy.
CONCLUSION
We found that baseline anemia and procedure-related
blood loss are independently associated with increased
risk of contrast-induced nephropathy in patients with
coronary artery disease treated with percutaneous coro-
nary interventions. While lower baseline hematocrit in-
creases the rates of contrast-induced nephropathy in
patients with any given eGFR level, patients com-
bining both low preprocedure hematocrit and eGFR
are at the highest risk to develop contrast-induced
nephropathy. High prevalence of patients with low
hematocrit, a potentially modifiable risk factor for
contrast-induced nephropathy, and unfavorable impact
of contrast-induced nephropathy on prognosis after per-
cutaneous coronary intervention merits studies to discern
the value of correction of low hematocrit in a prospec-
tively designed trial. Given the finding that a procedure-
related drop in hematocrit was associated with increased
risk of contrast-induced nephropathy, an attempt should
be made to reduce blood loss.
Reprint request to George Dangas, M.D., Ph.D., 55 East 59th Street,
6th Floor, New York, NY 10022.
E-mail: gdangas@crf.org
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